experts doctor prevention malaria

Antimalarial drug boosts glioblastoma treatment

Reading now: 366
www.medicalnewstoday.com

The drug, called lumefantrine, may improve the success rate of radiation and chemotherapy treatments for a severe type of brain cancer.

Glioblastoma multiforme (GBM) is an especially aggressive form of cancer that is difficult to treat. With currently available therapies, the 5-year survival rate for people with GBM is 5.6%.

Doctors currently have no way of preventing the recurrence of the disease. Experts estimate that malignant brain tumors and cancers of the central nervous system — 81% of which are glioblastomas — kill 241,000 people each year worldwide. New research finds that lumefantrine, a drug approved by the Food and Drug Administration (FDA) to combat malaria, can enhance the effectiveness of the primary drug used to treat GBM.

Read more on medicalnewstoday.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA